Christopher Croot, MD
Hematology & Oncology · Pikeville, KYNPI 1053318717
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,852 of the $17,408 with a category attached, or 73.8%. It is spread thinly across 60 manufacturers, the largest accounting for just 17.8%.
Across 687 payments — averaging $25.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- E.r. Squibb & Sons, L.L.C.$2K
- AstraZeneca$1K
- Johnson & Johnson$1K
- Merck$1K
- Daiichi Sankyo Inc.$823
- plus $8K from 54 others
Across 121 payments — averaging $4657.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$285K
- GSK$104K
- Radius Health, Inc.$59K
- Stemline Therapeutics Inc.$57K
- Eli Lilly$14K
- Ipsen Bioscience Inc.$12K
- plus $32K from 5 others
What the payments were for
- Consulting fees$3,35119%
- Food & beverage$12,85274%
- Education$1,2057%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,408 in reported general payments places this provider in the 85th percentile of 143 hematology & oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 39 | $541,313 |
| PomalystPomalidomide | 27 | $531,002 |
| RevlimidLenalidomide | 21 | $367,484 |
| Lenalidomide | 26 | $357,089 |
| JakafiRuxolitinib Phosphate | 14 | $248,601 |
| CalquenceAcalabrutinib Maleate | 14 | $215,580 |
| IbrancePalbociclib | 13 | $199,780 |
| ErleadaApalutamide | 13 | $170,826 |
| Abiraterone Acetate | 44 | $152,348 |
| GleevecImatinib Mesylate | 11 | $114,687 |
| Imatinib Mesylate | 33 | $55,955 |
| EliquisApixaban | 80 | $50,771 |
| XareltoRivaroxaban | 28 | $23,105 |
| Deferasirox | 23 | $13,355 |
| CreonLipase/Protease/Amylase | 12 | $8,976 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $637 | $541,31339 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $2,186 | $531,00227 claims |
| Bristol Myers SquibbRevlimid | $350 | $367,48421 claims |
| PfizerIbrance, Eliquis | $555 | $250,55193 claims |
| Incyte CorporationJakafi | $292 | $248,60114 claims |
| AstraZenecaCalquence | $1,346 | $215,58014 claims |
| Johnson & JohnsonErleada, Xarelto | $1,272 | $193,93141 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $67 | $152,34844 claims |
| NovartisGleevec | $3,102 | $114,68711 claims |
| AbbVieCreon | $210 | $8,97612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 143 hematology & oncology providers in Kentucky.
Other hematology & oncology in Pikeville
- Aasems JacobPikeville$19K
- Mohamed El DinaliPikeville$7K
- Firas BadinLexington$1.6M
- Vivek SharmaLouisville$647K
- Goetz KloeckerLouisville$584K
- Nicola JabbourLexington$563K
- Jeffrey HargisLouisville$450K
- Mohamed HegaziLouisville$380K
- Khuda KhanLouisville$359K
- Jaspreet GrewalLouisville$280K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.